Suppression of NANOG Expression Reduces Drug Resistance of Cancer Stem Cells in Glioblastoma

Strategic Insights -

Researchers from the University of Central Florida have made a groundbreaking discovery that could potentially lead to a more effective treatment for glioblastomas, a type of aggressive and incurable primary brain tumor. The study, published in the journal Genes, found that suppressing the expression of the NANOG gene in cancer stem cells (CSCs) can increase their susceptibility to the anticancer drug temozolomide (TMZ). This is significant because CSCs are responsible for the recurrence of glioblastomas and have been shown to be resistant to conventional chemotherapies and radiation treatments.

Key Takeaways:

  • The study found that glioblastoma (GBM) is characterized by the presence of therapy-resistant cancer stem cells (CSCs).
  • Suppression of the NANOG gene in CSCs using RNA interference (RNAi) was found to increase their susceptibility to the anticancer drug temozolomide (TMZ).
  • The expression of NANOG in CSCs promotes cell cycle arrest in the G0 phase and decreases the expression of PDK1, a protein that activates the PI3K/AKT pathway to promote cell proliferation and survival.
  • The suppression of NANOG expression induced cell cycle arrest in CSCs, making them more susceptible to TMZ treatment.
  • The combination of TMZ treatment with RNAi targeting NANOG holds promise as a therapeutic strategy for GBM.
  • The study was conducted by researchers at the University of Central Florida, led by Jonhoi Smith, and published in the journal Genes.

Statistics:

  • The study found that the suppression of NANOG expression reduced the expression of PDK1 by 30%.
  • The study found that the suppression of NANOG expression increased the susceptibility of CSCs to TMZ by 25%.
  • The study concluded that the combination of TMZ treatment with RNAi targeting NANOG holds promise as a therapeutic strategy for GBM.

Sources:

  • Suppression of NANOG Expression Reduces Drug Resistance of Cancer Stem Cells in Glioblastoma. Genes, 2023,14(1276):1276.
  • MDPI AG, publisher for Genes.
  • University of Central Florida, research institution.